Diaceutics PLC (DXRX) - Total Liabilities
Based on the latest financial reports, Diaceutics PLC (DXRX) has total liabilities worth GBX7.18 Million GBX (≈ $873.84 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Diaceutics PLC - Total Liabilities Trend (2015–2024)
This chart illustrates how Diaceutics PLC's total liabilities have evolved over time, based on quarterly financial data. See Diaceutics PLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Diaceutics PLC Competitors by Total Liabilities
The table below lists competitors of Diaceutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Generation Income Properties Inc
NASDAQ:GIPR
|
USA | $66.53 Million |
|
Cluey Ltd
AU:CLU
|
Australia | AU$6.73 Million |
|
KARELIAN DIA.R. EO-00025
F:KJY1
|
Germany | €2.15 Million |
|
AVRO INDIA LIMITED
NSE:AVROIND
|
India | Rs369.88 Million |
|
Sienna Resources Inc
V:SIE
|
Canada | CA$137.82K |
|
Ucommune International Ltd
NASDAQ:UK
|
USA | $74.20 Million |
|
Aptitude Software Group PLC
LSE:APTD
|
UK | GBX47.95 Million |
|
Gossan Resources Ltd
V:GSS
|
Canada | CA$146.46K |
Liability Composition Analysis (2015–2024)
This chart breaks down Diaceutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Diaceutics PLC stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diaceutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diaceutics PLC (2015–2024)
The table below shows the annual total liabilities of Diaceutics PLC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX8.76 Million ≈ $1.07K |
+57.66% |
| 2023-12-31 | GBX5.56 Million ≈ $676.25 |
-3.20% |
| 2022-12-31 | GBX5.74 Million ≈ $698.64 |
+31.58% |
| 2021-12-31 | GBX4.36 Million ≈ $530.97 |
+33.01% |
| 2020-12-31 | GBX3.28 Million ≈ $399.20 |
+46.54% |
| 2019-12-31 | GBX2.24 Million ≈ $272.42 |
-56.78% |
| 2018-12-31 | GBX5.18 Million ≈ $630.37 |
+43.37% |
| 2017-12-31 | GBX3.61 Million ≈ $439.69 |
+48.82% |
| 2016-12-31 | GBX2.43 Million ≈ $295.45 |
+106.72% |
| 2015-12-31 | GBX1.17 Million ≈ $142.92 |
-- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more